AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Peptides immunogenic for HLA-A2+ cancer patients identified.
2004 JUL 14 - (NewsRx.com & NewsRx.net) -- Scientists have identified epidermal growth factor receptor-derived peptides immunogenic for HLA-A2+ cancer patients.
According to published research from Japan, "Epidermal growth factor receptor (EGFR) is one of the most appropriate target molecules for cancer therapy because of its relatively high expression in about one-third of all epithelial cancers in correlation with neoplasmic progression. With respect to EGFR-targeted therapies, antibodies and tyrosine-kinase inhibitors have been intensively studied, a novel EGFR-tyrosine-kinase inhibitor ZD1839 has been approved as an anticancer drug, and many other agents are now under clinical trial. In addition, cytotoxic T lymphocyte (CTL)-directed epitope peptides could be another class of compounds useful in EGFR-targeted therapies."
"However, there is presently no information on CTL-directed peptides of EGFR," said H. Shomura and collaborators at Kurume University and Hokkaido University. "Therefore, from the viewpoint of development of peptide-based cancer therapy, this study was intended to determine the EGFR-derived peptides recognized by both cellular and humoral immunities in HLA-A2+ epithelial cancer patients."
The researchers reported, "We herein report finding of two such types of EGFR-derived peptides at ...
- Gene Test May Change Treatment, Extend Life for Lung Cancer Patients; New Study...
- News wire article from: Ascribe Higher Education News Service July 10, 2008 700+ words
...as those who are EGFR negative when given...change the way lung cancer patients are treated in the...We believe that EGFR FISH is that tool." The EGFR FISH test, which...laboratories, so lung cancer patients around the world...
- Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2...
- Press release article from: PR Newswire March 12, 2009 700+ words
...cancer (NSCLC) with K-RAS or EGFR-activated tumours. The Principal...effectively targeted K-RAS in cancer patients," said Dr. Villalona-Calero...recurrent NSCLC with K-RAS or EGFR-activated tumours, who have...demonstrated mutations in K-RAS or EGFR, or EGFR gene amplification...
- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for...
- Press release article from: PR Newswire September 2, 2008 700+ words
...cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours. The Principal Investigator...had for some time treatments that target EGFR, K-RAS has been an elusive target...metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, who have not received...
- /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination...
- Press release article from: PR Newswire September 2, 2008 700+ words
...cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours. The Principal Investigator...had for some time treatments that target EGFR, K-RAS has been an elusive target...metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, who have not received...
- GENMAB'S HUMAX-EGFR ERADICATES TUMOURS IN MOUSE CANCER STUDIES.
- Press release article from: PR Newswire June 13, 2001 700+ words
...treatments targeting EGFr with monoclonal antibodies...a fully human anti-EGFr antibody has the potential...treatment for certain cancer patients that is effective at...clinical trial with HuMax-EGFr in cancer patients, expected later this...
- Genmab's HuMax-EGFr Eradicates Tumors in Mouse Cancer Studies.
- Press release article from: PR Newswire June 13, 2001 700+ words
...treatments targeting EGFr with monoclonal antibodies...a fully human anti-EGFr antibody has the potential...treatment for certain cancer patients that is effective at...clinical trial with HuMax-EGFr in cancer patients, expected later this...
- FDA approval granted for EGFR pharmDx.
- Newspaper article from: Biotech Week March 17, 2004 700+ words
...FDA) for use of its EGFR pharmDx kit as an aid in identifying colorectal cancer patients eligible for treatment...in the treatment of EGFR-expressing metastatic colorectal cancer patients in December 2003. EGFR pharmDx is already being...
- DakoCytomation Receives FDA Approval for EGFR pharmDx(TM).
- Press release article from: PR Newswire February 16, 2004 700+ words
...Administration for use of its EGFR pharmDx(TM) kit as...identifying colorectal cancer patients eligible for treatment...in the treatment of EGFR-expressing metastatic colorectal cancer patients in December 2003. EGFR pharmDx is already being...